Rational Design of Multiclade Coronavirus Spike Immunodominant Domain Nanoparticles Elicit Broad Antibody Responses
Christian K. O. DzuvoriD, Sydney P. Moak, Lindsay R. McManusiD, Abigail Thomas, Abigail E. DzordzormeiD, Tae‐Woo KimiD, Jeswin JosephiD, Valerie Foley, Ingelise J. GordoniD, Laura NovikiD, LaSonji A. HolmaniD, Lesia K. DropuliciD, Ryan P. McNamaraiD, Kizzmekia S. CorbettiD
Abstract
Four seasonal endemic human coronaviruses (EhCoVs), HKU1-CoV, OC43-CoV, 229E-CoV, and NL63-CoV, are culprits of mild upper respiratory and periodic severe diseases in vulnerable populations. Despite their prevalence, understanding EhCoVs antigenic and immune signatures remains elusive. SARS-CoV-2 has evolved as the fifth EhCoV, requiring seasonal vaccination in most parts of the world, and currently, no other EhCoV vaccines are available. SARS-CoV-2 co-infection with EhCoVs increases disease severity; thus, combined vaccination may provide increased protection against seasonal EhCoVs overall. Here, we explored Spike (S) receptor binding domain (RBD) vs. N-terminal domain (NTD) B-cell immunodominance in EhCoV-positive convalescent donors and immunogenicity in mice. We found that while antibody and B-cell isotypes were relatively dominant to S NTD, mice immunized with S RBD elicited significantly higher binding and neutralizing antibody (nAb) responses. With that knowledge, we used computational methods to infer that EhCoV S sequences evolve into two main clades and designed chimeric immunodominant domains (IDDs) from both clades for each EhCoV. IDDs were scaffolded onto two-component nanoparticles (NPs) displaying each IDD separately (monovalent IDD NP); three {beta}-EhCoV IDDs (Mosaic-3 IDD NP); or five EhCoVs IDDs (Mosaic-5 IDD NP). Mice immunized with mosaic IDD NPs, but not soluble IDD antigens nor monovalent IDD NPs, elicited potent, broadly cross-reactive binding and neutralizing antibody (Ab) responses against SARS-CoV-2 variants, other EhCoVs, and Sarbecoviruses. System serology revealed that all four IDD immunogens elicited distinct Ab subclasses and Fc-effector functions, with mosaic-5 IDD NPs eliciting the most de novo Ab subclasses, distributions, and broader Fc-mediated immune mechanisms. Dissection of vaccine-immune sera revealed polyclonal Ab responses against multiple non-overlapping cross-reactive S epitopes. Due to elicitation of broad Ab responses with combinatory functionality, IDD NPs open new horizons for developing first-in-class supraseasonal EhCoV vaccine candidates, with potential to decrease frequent SARS-CoV-2 sequence updates and protect against other EhCoVs. Moreover, elicitation of Ab breadth that spans pandemic-threat Sarbecoviruses gives mosaic IDD NPs promise towards pandemic preparedness.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 2
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Mosaic receptor-binding domain nanoparticles induce protective immunity against SARS-CoV-2 challenges
- Antibody repertoire induced by SARS-CoV-2 spike protein immunogens
S. Ravichandran, E. M. Coyle, … S. Khurana·bioRxiv·May 12, 2020
- Phylogeny-driven design of broadly protective sarbecovirus receptor-binding domain nanoparticle vaccines
Amin Addetia, Alexandra Schäfer, … David Veesler·bioRxiv·May 11, 2025
- Neutralizing monoclonal antibodies elicited by mosaic RBD nanoparticles bind conserved sarbecovirus epitopes
C. Fan, A. A. Cohen, … P. J. Bjorkman·bioRxiv·Jun 28, 2022
- A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2
- Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines
A. C. Walls, M. C. Miranda, … Veesler·bioRxiv·Mar 15, 2021